Back to research
    Bioregulator

    Normoftal (Lys-Glu): What the KE Dipeptide Research Shows

    November 20267 min readBy the Peptx research team

    Normoftal is published as KE, the dipeptide Lys-Glu, the same sequence as Vilon. What the retinal cell culture studies found, which retina studies used other peptides, what is only a vendor claim, and what is not known.

    Quick Answer

    Normoftal is a Khavinson short peptide that the developer's 2014 review lists as KE, the dipeptide lysine-glutamic acid, at 275 Da: the same published sequence as Vilon. The developers assign it to the retina. The only published work on KE and eye cells is cell culture from the same St Petersburg group, no paper on PubMed names Normoftal, and no trial is registered.

    Key facts

    • Published sequence: Lys-Glu (KE), listed as "Normoftal (KE)" in the developer's 2014 review.
    • Formula and mass: C11H21N3O5, 275.3 Da (PubChem CID 7010502, the record for Lys-Glu).
    • CAS number (Lys-Glu): 45234-02-4. FDA UNII: H34V7IM5ML.
    • Same published sequence as: Vilon.
    • Evidence for KE in eye cells: cell culture only, from the developing group.
    • Human trials (November 2026): none registered; no paper on PubMed names Normoftal.
    • Status: not authorised as a medicine in the UK, EU or US; sold in Russia as a dietary supplement.

    Normoftal is one of the less familiar names from the Khavinson bioregulator range, and it is easy to find it described as an eye peptide with confident claims attached. The published record is much thinner. This article sets out what the name refers to, what has been studied, and which findings belong to other compounds.

    What is Normoftal?

    Vladimir Khavinson's group at the St Petersburg Institute of Bioregulation and Gerontology developed a series of short synthetic peptides, two to four amino acids long, and assigned each to an organ. Our overview of Khavinson bioregulators explains the programme. In a 2014 review, the group's table of synthesised peptides lists "Normoftal (KE)" with the activity "regulation of the functions of the retina" and a molecular mass of 275 Da (Khavinson, 2014).

    KE is the one-letter code for lysine joined to glutamic acid. The same table lists "Vilon (KE)", also at 275 Da, as a stimulant of tissue regeneration, and the group's other papers assign Vilon to the thymus and immune system. PubChem's record for Lys-Glu (CID 7010502) gives both Vilon and Normophthal as synonyms. On the published evidence, then, Normoftal and Vilon are two names for one molecule. Our Vilon research article covers the KE dipeptide in depth, including the DNA-binding evidence.

    In Russia, Normoftal is sold as capsules registered as a dietary supplement (BAA). The RLS drug reference lists the contents as the peptide complex AKS-G (lysine, glutamic acid).

    Where did the retina link come from?

    The group's eye work began with Retinalamin, a polypeptide extract of animal retinas that is used clinically in Russia. A 2019 review from the group says that KE and the tetrapeptide AEDG were designed from an amino acid analysis of Retinalamin (Khavinson et al., 2019). That is the basis for assigning KE to the retina. The paper does not report the analysis itself, and the same dipeptide is assigned to the thymus under the name Vilon.

    What have studies of KE in eye cells found?

    • Embryonic retinal cell cultures (2013). The group studied KE and AEDG in cultured embryonic retinal cells and reported that both increased markers of differentiation in neurons and in retinal pigment epithelium cells, the layer that supports the light-sensing cells (Khavinson et al., 2013). The markers named in the group's later reviews include the transcription factors Brn3, Pax6, Prox1 and Vsx1 and the protein transthyretin.
    • Which peptide did what (2019 review). KE had the stronger effect on transthyretin, a pigment epithelium marker, while AEDG had more effect on the neuronal markers Vsx1, Pax6 and Brn3 (Khavinson et al., 2019).

    Both reports are short and come from the developing institute. A change in differentiation markers in a dish is an early laboratory signal; it does not show what happens in a living eye.

    Which retina studies used other peptides?

    The rat and human retina results cited for Khavinson eye peptides were not obtained with KE:

    • Campbell rats, a strain with inherited retinal degeneration: the studies indexed on PubMed tested Epitalon (AEDG) (Khavinson et al., 2003).
    • People with retinal degeneration: a 2002 report, covering Campbell rats and patients, tested Epitalon (Khavinson et al., 2002).
    • People with diabetic retinopathy: a 2001 Russian-language report described Retinalamin, Epithalamin and Cortexin, all extracts, given alongside standard care (Trofimova and Khavinson, 2001).

    None of these is a placebo-controlled trial of KE. Our Epitalon research article covers the AEDG retina work.

    What else has KE been studied for?

    Under the name Vilon, KE has been studied in thymus and immune cell cultures, in stem cell gene expression and in a 2000 study in female CBA mice that reported longer lifespan and fewer tumours (Khavinson et al., 2000), although, as our Vilon article notes, a fuller report from the group did not repeat the survival gain. A 2022 cell study with Italian co-authors found that Vilon and four other Khavinson peptides modulated inflammatory signalling in a human monocyte cell line (Avolio et al., 2022). Khavinson is a co-author of that paper too, so no fully independent group has yet published on KE.

    What is a vendor claim, and what is evidence?

    • Evidence: the published sequence (KE) and mass (275 Da), and cell culture findings on retinal differentiation markers from the developing group.
    • Developer's assignment, not tested: that Normoftal acts specifically on the retina. The same molecule is assigned to the thymus as Vilon.
    • Vendor claim: listings that present Normoftal as an eye or retina bioregulator with effects in people. No published trial supports that.

    What is not known yet?

    • Any controlled study of Normoftal. None is published or registered.
    • Independent replication. All KE eye work comes from one institute.
    • Tissue specificity. How one dipeptide could act selectively on the retina, or on the thymus, has not been shown.
    • Stability and exposure. The papers reviewed here do not report how long KE survives in blood or tissue, or whether it reaches the retina.

    The bottom line

    Normoftal is the Khavinson name for KE, the dipeptide Lys-Glu, assigned by its developers to the retina. It is the same published molecule as Vilon. The eye evidence for KE is two short cell culture reports from the developing group, and the rat and human retina studies often quoted alongside it used other preparations. As of November 2026 it is a research compound with no trials. See the Normoftal profile for identifiers, or browse bioregulator research compounds.

    References

    1. Avolio F, et al. (2022). Peptides Regulating Proliferative Activity and Inflammatory Pathways in the Monocyte/Macrophage THP-1 Cell Line. International Journal of Molecular Sciences. PubMed 35408963
    2. Khavinson VKh. (2014). Peptides, genome, aging. Advances in Gerontology 4:337-345. DOI 10.1134/S2079057014040134
    3. Khavinson VKh, et al. (2013). Peptidegic regulation of differentiation of embryonic retinal cells. Bulletin of Experimental Biology and Medicine. PubMed 23667897
    4. Khavinson V, et al. (2019). Molecular-Physiological Aspects of Regulatory Effect of Peptide Retinoprotectors. Stem Cell Reviews and Reports. PubMed 30859383
    5. Khavinson VKh, et al. (2003). Retinoprotective effect of Epithalon in campbell rats of various ages. Bulletin of Experimental Biology and Medicine. PubMed 12910293
    6. Khavinson V, et al. (2002). Pineal-regulating tetrapeptide epitalon improves eye retina condition in retinitis pigmentosa. Neuro Endocrinology Letters. PubMed 12195242
    7. Khavinson VK, et al. (2000). Effect of vilon on biological age and lifespan in mice. Bulletin of Experimental Biology and Medicine. PubMed 11140587
    8. Trofimova SV, Khavinson VKh. (2001). Effectiveness of bio-regulators in the treatment of diabetic retinopathy. Vestnik Oftalmologii. PubMed 11521426

    Frequently asked questions

    What is Normoftal made of?

    The developer's 2014 review lists Normoftal as KE: the dipeptide lysine-glutamic acid (Lys-Glu), molecular formula C11H21N3O5 and mass 275 Da. In Russia it is sold as a dietary supplement whose label lists a peptide complex of lysine and glutamic acid.

    Is Normoftal the same molecule as Vilon?

    By published sequence, yes. The same review lists both Vilon and Normoftal as KE at 275 Da, and PubChem gives Vilon and Normophthal as synonyms of Lys-Glu. The developers assign Vilon to the thymus and Normoftal to the retina.

    What has KE been shown to do in eye cells?

    In cultures of embryonic retinal cells, the developing group reported that KE and the tetrapeptide AEDG increased markers of differentiation in retinal neurons and pigment epithelium cells, with KE having the stronger effect on the pigment epithelium marker transthyretin. These are cell culture findings from one group.

    Has Normoftal been tested in animals or people?

    Not under that name in any study on PubMed, and no trial is registered on ClinicalTrials.gov as of November 2026. The rat and human retina studies from the same institute tested Epitalon, Retinalamin or Epithalamin, not KE.

    Is Normoftal a medicine?

    It is not authorised as a medicine in the UK, EU or US. In Russia it is sold as a dietary supplement. Peptx describes it only as a research compound for laboratory use.

    Related research

    What net peptide content meansBrowse the research library